ANNUAL REPORT - Department of Biotechnology
ANNUAL REPORT - Department of Biotechnology
ANNUAL REPORT - Department of Biotechnology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
As the clinical trials ae planned to be done following<br />
ICH-GCP guidelines, Contract Research<br />
Organization (CROs) have been engaged clinical<br />
trial and data management. CROs that have been<br />
firmed up are:<br />
�<br />
�<br />
�<br />
Neeman Medical International, New Delhi,<br />
Manipal Acunova Ltd, Bangalore<br />
Catalyst Clinsys Services Pvt Ltd, New Delhi<br />
Cell based immunotherapy<br />
Phase I studies on the development and clinical<br />
evaluation <strong>of</strong> Dendritic cell (D.C.) vaccine derived<br />
from autonomous mononuclear cells from peripheral<br />
blood <strong>of</strong> patients and primed with whole cell lysates<br />
from tumours <strong>of</strong> individual patients have been carried<br />
out at WIA Cancer Institute, Chennai. The data<br />
indicated that there was minimal or no toxicity or<br />
autoimmune reaction in the vaccinated patients<br />
whereas a DTH response was seen in 2/3 patients<br />
receiving primed DC and CD8 infiltration elevated in<br />
one patient indicating immune modulation. Though<br />
no objective tumor regression was seen, the studies<br />
were not intended to see the efficacy as it was carried<br />
out in extensively treated patients. Encouraged by<br />
the results, the Task Forces on “Vaccines and<br />
Diagnostics” and “Chronic Diseases Biology”<br />
suggested the need for setting up a full fledged<br />
“Centre for Cancer Immunotherapy” with several<br />
peripheral centers. A discussion meeting on “Center<br />
for Cancer Immunotherapy” was held at Cancer<br />
Institute (WIA), Chennai. Considering the high<br />
quality <strong>of</strong> on-going translational work, CI, Chennai is<br />
being considered as a Centre for Cancer<br />
Immunotherapy (CCI) with the peripheral units as<br />
Associated Centers for Cancer Immunotherapy<br />
(ACCI). Institutions likely to be linked as ACCI are<br />
NCCS, Pune; NII and AIIMS, New Delhi; ACTREC,<br />
Mumbai, TRF, New Delhi and RLS, Mumbai.<br />
Cancer Stem Cells: Glioblastoma multiformes<br />
(GBM) represents one <strong>of</strong> the most malignant brain<br />
tumors characterized by intense proliferation,<br />
widespread invasion and poor prognosis. Tumor<br />
DBT Annual Report 2006-07<br />
114<br />
initiating cancer stem cells (CSC) have been found<br />
within GBM. In a study to understand the signaling<br />
cascades involved in the proliferation and<br />
differentiation, CSC from GBM cell line U87MG have<br />
been generated by a group at NBRC, Manesar. It is<br />
now proposed to study intrinsic circuitries regulating<br />
gene programs involved in maintenance and<br />
differentiated.<br />
A B<br />
Neurosciences<br />
Cancer Stem Cells generated from<br />
gBM cell line U87MG<br />
The <strong>Department</strong> is supporting R&D projects in the<br />
area <strong>of</strong> neurosciences that , includes projects on<br />
neuronal aging, cognitive malfunctioning in normal<br />
and diseased conditions, neuro-genetic disorders<br />
etc. The area has been identified as a priority for the<br />
next plan bringing together scientists, clinical<br />
partners and industries. The <strong>Department</strong> is<br />
proposing to set up “Centers <strong>of</strong> Excellence” on<br />
stroke, vascular biology, dementia and basic neuronbiology<br />
in close association with NBRC, Manesar;<br />
AIIMS, New Delhi; CMC, Vellore; NCBS, Bangalore;<br />
and NIMHANS, Bangalore It is proposed to hold a<br />
brainstorming on “Stroke” .<br />
Metabolic Disorders<br />
An elevated level <strong>of</strong> homosysteine has been<br />
implicated as an independent risk factor in<br />
cardiovascular diseases as well as in a variety <strong>of</strong>